Cas:56461-98-4 2,6-dichloro-4-toluidine manufacturer & supplier

Chemical Name:2,6-dichloro-4-toluidine

CAS.NO:56461-98-4

Synonyms:Benzenamine, 2,6-dichloro-4-methyl-;3.5-Dichlor-4-amino-toluol;2,6-Dichloro-4-methylaniline;Benzenamine,2,6-dichloro-4-methyl;2,6-dichloro-4-methyl-aniline;2,6-Dichloro-4-toluidine;2,6-Dichlor-4-methyl-anilin;2.6-Dichlor-p-toluidin;m-Dichlor-p-toluidin;CL9144

Molecular Formula:C₇H₇Cl₂N

Molecular Weight:176.043

HS Code:2921430090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:244.7±35.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.600

PSA:26.02000

Exact Mass:174.995560

LogP:3.36

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Benzenamine, 2,6-dichloro-4-methyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,CL9144 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzenamine,2,6-dichloro-4-methyl Use and application,2,6-Dichloro-4-toluidine technical grade,usp/ep/jp grade.

Related News: In China, Wuhan used to be known as a city of cherry blossoms, an economic engine of the central heartland, and the birthplace of a century-old revolution that brought down the country’s last imperial dynasty. 2,6-dichloro-4-toluidine manufacturer Britons being brought from Wuhan to the UK are being placed in quarantine at Arrowe Park Hospital in the Wirral, northwest England, Raab said. 2,6-dichloro-4-toluidine supplier As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. 2,6-dichloro-4-toluidine vendor Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world. 2,6-dichloro-4-toluidine factory As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL.